Alexander Levitzki
YOU?
Author Swipe
View article: EGFR-targeted affibody–polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR
EGFR-targeted affibody–polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR Open
The epidermal growth factor receptor (EGFR) is aberrantly activated in many human epithelial cancers. This report presents the preparation, purification, and the anti-cancer potency of an anti-EGFR affibody (Z EGFR 1907’ )-polyethylenimine…
View article: Figure S5 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Figure S5 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Protein-protein interaction (A) and pathway analysis (B) for sites exhibiting rapid increase, then decrease (Cluster 5).
View article: Supplementary Figure S2 from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Supplementary Figure S2 from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment Open
Supplementary Figure illustrating the difference in cytokine mRNA and protein expression following treatment of BT-474 with pIC/PPHAffibody and pIC/PPCys
View article: Supplementary Figure S2 from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Supplementary Figure S2 from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment Open
Supplementary Figure illustrating the difference in cytokine mRNA and protein expression following treatment of BT-474 with pIC/PPHAffibody and pIC/PPCys
View article: Supplementary Materials and Methods and Supplementary Figure Legends from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Supplementary Materials and Methods and Supplementary Figure Legends from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment Open
Supplementary Material and methods
View article: Figure S3 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Figure S3 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Characterization of NT157-induced SFK activation.
View article: Table S2 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Table S2 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Summary of kinase panel used for testing of NT157 activity.
View article: Figure S1 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Figure S1 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Heatmap for Cluster 4.
View article: Table S1 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Table S1 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Summary of phosphoproteomic profiling data.
View article: Figure S4 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Figure S4 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Heatmap for Cluster 5.
View article: Figure S5 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Figure S5 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Protein-protein interaction (A) and pathway analysis (B) for sites exhibiting rapid increase, then decrease (Cluster 5).
View article: Supplementary Tables S1-S3 and Supplementary Figures S1-S8 from The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer
Supplementary Tables S1-S3 and Supplementary Figures S1-S8 from The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer Open
Supplementary Table and Figures: Table S1: Prostate cancer tumor microarray characteristics Fig. S1: IRS antibody validation Fig. S2: Effect of NT157 on the viability of benign prostatic cell line Fig. S3: Immunoblot analysis of cell cycle…
View article: Supplementary Figure S3 from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Supplementary Figure S3 from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment Open
Supplementary Figure demonstrating the effect of pIC/PPHAffibody treatment on RENCA HER2 cell survival in vitro and in vivo by immunohistochemistry staining for c-caspase-3
View article: Figure S7 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Figure S7 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Protein-protein interaction (A) and pathway analysis (B) for sites exhibiting delayed induction upon NT157 treatment (Cluster 3).
View article: Data from The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer
Data from The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer Open
Insulin-like growth factor (IGF) signaling is associated with castrate-resistant prostate cancer (CRPC) progression. Insulin receptor substrates 1 and 2 (IRS1/2) mediate mitogenic and antiapoptotic signaling from IGF1 receptor (IGF1R), ins…
View article: Supplementary Materials and Methods and Supplementary Figure Legends from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Supplementary Materials and Methods and Supplementary Figure Legends from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment Open
Supplementary Material and methods
View article: Figure S3 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Figure S3 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Characterization of NT157-induced SFK activation.
View article: Data from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Data from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
The small-molecule drug NT157 has demonstrated promising efficacy in preclinical models of a number of different cancer types, reflecting activity against both cancer cells and the tumor microenvironment. Two known mechanisms of action are…
View article: Figure S4 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Figure S4 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Heatmap for Cluster 5.
View article: Figure S2 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Figure S2 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Heatmap for Cluster 1.
View article: Supplementary Tables S1-S3 and Supplementary Figures S1-S8 from The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer
Supplementary Tables S1-S3 and Supplementary Figures S1-S8 from The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer Open
Supplementary Table and Figures: Table S1: Prostate cancer tumor microarray characteristics Fig. S1: IRS antibody validation Fig. S2: Effect of NT157 on the viability of benign prostatic cell line Fig. S3: Immunoblot analysis of cell cycle…
View article: Figure S1 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Figure S1 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Heatmap for Cluster 4.
View article: Figure S6 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Figure S6 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Heatmap for Cluster 3.
View article: Table S2 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Table S2 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Summary of kinase panel used for testing of NT157 activity.
View article: Table S1 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Table S1 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Summary of phosphoproteomic profiling data.
View article: Data from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Data from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment Open
The development of targeted therapies that affect multiple signaling pathways and stimulate antitumor immunity is greatly needed. About 20% of patients with breast cancer overexpress HER2. Small molecules and antibodies targeting HER2 conv…
View article: Figure S6 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Figure S6 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Heatmap for Cluster 3.
View article: Supplementary Figure S1 from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Supplementary Figure S1 from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment Open
Supplementary Figure illustrating the expression of TLR3 in cell line that deferentially express HER2
View article: Supplementary Figure Legends from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Supplementary Figure Legends from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks Open
Supplementary Figure Legends